Bronchiectasis
Conditions
Interventions
44 Adult patients with non-fibrocystic bronchiectasis and moderate to severe obstructive sleep apnea will use a PAP device with defined treatment pressure during PSG, every night for three months. The
EPSTEIN et al., 2009
et al., 2012, PELOSI et al, 2017). The subjective adherence to the use of the treatment will be evaluated by filling in the sleep diary, which includes the use of PAP. The patients will return to the
Device
Sponsors
Centro Universitário Augusto da Motta
Centro Universitário Augusto da Motta
Eligibility
Age
No minimum to 90 Years
Inclusion criteria
Inclusion criteria: Patients with clinical diagnosis of BNF (after confirmation by HRCT and sweat test) of both genders; between 18 and 90 years old; after agreeing to participate in the study; signing the ICF; with no cognitive deficit that would interfere in the comprehension to answer the questionnaires; clinical stability at least 1 month; long-term bronchodilator use; presence of OSA confirmed by PSG.
Exclusion criteria
Exclusion criteria: Patients with bronchiectasis due to CF (chloride level in sweat> 60 mmol / L); smoking history; presence of other pulmonary diseases (eg COPD and asthma) and / or other comorbidities that could influence the diagnosis and/or prognosis in the outcome of the disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in mean apnea and hypopnea index determined by PSG and increase in walking meters at 6MWT and faster to achieve TGlittre after 3 months of PAP use in adults with BNF and OSA. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pulmonary function was complete with improvement in FEV1 and FVC, reduced levels of inflammatory biomarkers collected in the blood, improved quality of life questionnaires and a faster rate of ADLs after 3 months of PAP use in adults with BNF and AOS. | — |
Countries
Brazil
Contacts
Public ContactNewton Faria Júnior
Centro Universitário Augusto Motta - UNISUAM
Outcome results
None listed